Although the study results did not lead to the registration of durvalumab, the authors highlighted the fact that in EGFR-mutated patients with ≥25% of tumor cells expressing PD-L1 the activity of durvalumab was visible and further investigation is necessary (Table 2) [26]. The gene discussed is EGFR; the disease is neoplasm.